Muddy Waters is Short PeptiDream, Inc. (4587.JP) November 6, 2019 When wooing retail investors, Chairman Kiichi Kubota likes to compare non-standard peptide drugs to a Jaguar sports coupe (while comparing other drug types to a dump truck and motor scooter). These Terms of Use govern current reports published by Muddy Waters Research and supersede any prior Terms of Use for older reports of Muddy Waters Research, which you may download from the Muddy Waters Research’s website. With equity markets at records, Muddy Waters is finding “more large, liquid problematic companies than before, but at the same time, increasing levels of investor apathy,” Block said by email. PeptiDream fell as much as 5.5% in Tokyo trading Thursday after the short seller questioned the level of activity at the company’s drug development partnerships with pharmaceutical companies. PeptiDream, in a statement after the market close, refuted contents of the short seller’s report, saying it holds a “completely different view” from Muddy Waters. In relation to the United Kingdom, the research and materials on this website are being issued only to, and are directed only at, persons who are Permitted Recipients and, without prejudice to any other restrictions or warnings set out in these Terms of Use, persons who are not Permitted Recipients must not act or rely on the information contained in any of the research or materials on this website. In no event shall Muddy Waters Research, Muddy Waters Capital or any Muddy Waters Related Persons be liable for any claims, losses, costs or damages of any kind, including direct, indirect, punitive, exemplary, incidental, special or, consequential damages, arising out of or in any way connected with any information on this website. The failure of Muddy Waters Research or Muddy Waters Capital to exercise or enforce any right or provision of these Terms of Use shall not constitute a waiver of this right or provision. This website is owned by Muddy Waters Research. Neither Muddy Waters Research nor Muddy Waters Capital will update any report or information on its website to reflect changes in positions that may be held by a Muddy Waters Related Person. Copyright © 2020 Muddy Waters Research, All Rights Reserved. Muddy Waters Capital is short PeptiDream, Inc. because we believe it is more stock story than substance, and the market is deluded as to its potential for commercializing drugs. Reports are based on generally available information, field research, inferences and deductions through the applicable Muddy Waters Entity’s due diligence and analytical process. The reports on this website have been prepared by either Muddy Waters, LLC (“Muddy Waters Research”) or Muddy Waters Capital LLC (“Muddy Waters Capital”). You agree that use of the research on this website is at your own risk. Have a confidential tip for our reporters? All reports are for informational purposes only. The firm is part of a handful of Japanese biotech ventures that have grown into billion-dollar companies, which also includes Sosei Group Corp., the drugmaker that now accounts for more than 7% of the Mothers Index of smaller shares. You accept all risks in relying on the information on this website. To the best of the applicable Muddy Waters Entity’s ability and belief, all information contained herein is accurate and reliable, and has been obtained from public sources that the applicable Muddy Waters Entity believe to be accurate and reliable, and who are not insiders or connected persons of the Covered Issuers or who may otherwise owe a fiduciary duty, duty of confidentiality or any other duty to the Covered Issuer (directly or indirectly). If you access this website, download or receive the contents of reports or other materials on this website as an agent for any other person, you are binding your principal to these same Terms of Use. PeptiDream touts its 19 major partnerships and 101 discovery programs, but half of its partnerships are … You agree that the information on this website is copyrighted, and you therefore agree not to distribute this information (whether the downloaded file, copies / images / reproductions, or the link to these files) in any manner other than by providing the following link: https://www.muddywatersresearch.com/research/. Latest Reports. With respect to their respective research reports, Muddy Waters Research and Muddy Waters Capital makes no representation, express or implied, as to the accuracy, timeliness, or completeness of any such information or with regard to the results to be obtained from its use. Muddy Waters Capital does not render investment advice to anyone unless it has an investment adviser-client relationship with that person evidenced in writing. To even remotely justify investor expectations, PeptiDream would likely need to succeed in meeting drug development milestones at rates many times industry norms. Post was not sent - check your email addresses! If you access this website, download or receive the contents of reports or other materials on this website on your own behalf, you agree to and shall be bound by these Terms of Use. Updates with PeptiDream response in third paragraph. If you are in the United Kingdom, you confirm that you are accessing research and materials as or on behalf of: (a) an investment professional falling within Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “FPO”); or (b) high net worth entity falling within Article 49 of the FPO (each a “Permitted Recipient”). This is not an offer to sell or a solicitation of an offer to buy any security. The research and reports presented on this website express the opinion of the applicable Muddy Waters Entity only. You understand and agree that Muddy Waters Capital does not have any investment advisory relationship with you or does not owe fiduciary duties to you. You further agree that any dispute between you and Muddy Waters Research and its affiliates arising from or related to this report and / or the Muddy Waters Research website or viewing the material hereon shall be governed by the laws of the State of California, without regard to any conflict of law provisions. But we believe the coolness of PeptiDream’s technology amounts to at best a very small business opportunity. You represent that you have sufficient investment sophistication to critically assess the information, analysis and opinion on this website. Before it's here, it's on the Bloomberg Terminal. PeptiDream, in a statement after the market close, refuted contents of the short seller’s report, saying it holds a “completely different view” from Muddy Waters. But to date, PeptiDream has underperformed these industry norms, despite being in operation since 2006. Sign up for our mailing list and receive research reports and other related news and updates from Muddy Waters Research. You agree that regardless of any statute or law to the contrary, any claim or cause of action arising out of or related to this website or the material on this website must be filed within one (1) year after the occurrence of the alleged harm that gave rise to such claim or cause of action, or such claim or cause of action be forever barred. PeptiDream has really cool technology – it can put trillions of different peptides in a single test tube!

muddy waters peptidream

Program To Insert A Node In Linked List In C++, Wusthof Electric Knife Sharpener, Gsx Apple Unlocking Method, 2012 Harley Davidson Sportster 883 Weight, Poshland Tracker Knife Review, Smallmouth Bass Vs Largemouth, Roasted Curry Powder In Sinhala, Beyond Meat Valuation, Can You Become A Judge Without Being A Lawyer,
muddy waters peptidream 2020